Vignesh Rajendiran

This study demonstrates the use of base editors to precisely correct various β-thalassemic mutations in human erythroid cells, showing efficient and scarless mutation correction with normal hemoglobin variants.

This study uses CRISPR base editing to identify novel mutations in the HBG promoter that increase fetal hemoglobin expression without harmful effects.